ZYME
Zymeworks Inc.
Next earnings Aug 5, 2026 · consensus $-0.41 EPS, $21.1M rev
Last earnings -3.7% on 2026-05-07
$24.15
▲ +1.60%$24.15▲ +93.66%
over 1Y
L $12.02EODHDH $28.56
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.6%
1W+3.8%
1M-2.6%
3M-0.1%
YTD-9.3%
1Y+93.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 20 analysts
Buy
Revenue grew 38.9% YoY; but unprofitable (net margin -76.6%).
Revenue (FY2025) $106M · FY2025
Zymeworks Inc. shows $106M in FY2025 revenue (+38.9% YoY), a -76.6% net margin, and -30.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $26.7M | $412M | $76.0M | $76.3M | $106M |
| Gross profit | — | — | — | — | — |
| Operating income | -$216M | $131M | -$138M | -$137M | -$92.5M |
| Net income | -$212M | $124M | -$119M | -$123M | -$81.1M |
| Diluted EPS | -$4.61 | $1.90 | -$1.72 | -$1.62 | -$1.08 |
| Net margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.74B
EV / EBITDA—
EV / Sales16.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-4.6%
FCF yield-1.9%
Quality & risk
ROIC (est.)-27.2%
Free cash flow-$34.5M
Total debt—
Net cash$41.2M
Altman Z-Score9.98 safe
Piotroski F-Score4/7
Capital returns
Buyback yield2.3%
Dividend yield (est.)—
Shareholder yield2.3%
Shares Δ YoY+6.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-05-132026-05-15open ↗3Period ending 2026-05-132026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗SCHEDULE 13GFiling2026-04-15open ↗4Period ending 2026-04-092026-04-10open ↗4Period ending 2026-04-092026-04-10open ↗3Period ending 2026-04-092026-04-10open ↗3Period ending 2026-04-092026-04-10open ↗4Period ending 2026-04-062026-04-07open ↗
Frequently asked
- Is Zymeworks Inc. (ZYME) a buy?
- ZYME currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 38.9% YoY; but unprofitable (net margin -76.6%).
- What is Zymeworks Inc.'s quality score?
- ZYME scores 49.11764705882352/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001937653, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:49:48 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.